{"nct_id":"NCT06357533","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2024-04-11","start_date_type":"ACTUAL","primary_completion_date":"2028-04-24","primary_completion_date_type":"ESTIMATED","completion_date":"2030-05-24","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}